Liver Cancer Trial, Recruiting NCT07417800 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT07417800
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with liver cancer (hepatocellular carcinoma) confirmed by a laboratory examination of tissue
  • You are older than 18 years of age
  • You have had surgery to completely remove your liver cancer, with no cancer cells left at the edges of the removed tissue (known as a "clear margin" surgery)
  • Tissue samples from your surgery are available and in good enough condition to be scanned and analysed digitally
  • Your full medical records and follow-up information are available and accessible
  • You have complete pre- and post-surgery CT or MRI scan images of good quality, taken using consistent scanning settings, suitable for computer-based analysis

Who may not be able to join:

  • Important parts of your medical records or follow-up information are missing
  • You have been diagnosed with a second, separate cancer in another part of your body
  • Your surgery did not fully remove the cancer, meaning some cancer cells were left behind at the surgical edges
  • Your tissue samples are in poor condition (for example, faded, folded, or damaged) and cannot be used for digital scanning or analysis

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: ding yuan, doctor, Second Affiliated Hospital, School of Medicine, Zhejiang University

Phone: +86 18858101960

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 November 2025
Est. completion
1 January 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

recurrence free survival; recurrence rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov